These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

145 related articles for article (PubMed ID: 38669474)

  • 21. Glycemic and Cost Outcomes among Hispanic/Latino People with Type 2 Diabetes in the USA Initiating Dulaglutide versus Basal Insulin: a Real-World Study.
    Hoog M; Maldonado JM; Wangia-Dixon R; Halpern R; Buysman E; Gremel GW; Huang A; Konig M
    Diabetes Ther; 2024 Apr; 15(4):855-867. PubMed ID: 38427164
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.
    Edelman S; Cassarino D; Kayne D; Dex T; Li X; Pasquel FJ
    J Manag Care Spec Pharm; 2022 Sep; 28(9):958-968. PubMed ID: 36001104
    [No Abstract]   [Full Text] [Related]  

  • 23. Real-world clinical outcomes following treatment intensification with GLP-1 RA, OADs or insulin in patients with type 2 diabetes on two oral agents (PATHWAY 2-OADs).
    Desouza C; Kirk AR; Mangla KK; Wolden ML; Lingvay I
    BMJ Open Diabetes Res Care; 2020 Dec; 8(2):. PubMed ID: 33376084
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Evaluation of Outcomes After Initiating Triple Antidiabetic Therapy with a GLP-1 RA in an Integrated Health Care System.
    Lee SM; Aboubechara N; Niu F; Ledesma VM; Patel YA; Millares M; Hui RL
    J Manag Care Spec Pharm; 2019 Mar; 25(3):350-356. PubMed ID: 30816819
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A Systematic Literature Review and Network Meta-Analysis Comparing Once-Weekly Semaglutide with Other GLP-1 Receptor Agonists in Patients with Type 2 Diabetes Previously Receiving Basal Insulin.
    Witkowski M; Wilkinson L; Webb N; Weids A; Glah D; Vrazic H
    Diabetes Ther; 2018 Jun; 9(3):1233-1251. PubMed ID: 29713961
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Use of the FreeStyle Libre system and diabetes treatment progression in T2DM: Results from a retrospective cohort study using a Canadian private payer claims database.
    Harris SB; Levrat-Guillen F
    Diabetes Obes Metab; 2023 Jun; 25(6):1704-1713. PubMed ID: 36811267
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Model-based simulation of glycaemic effect and body weight loss when switching from semaglutide or dulaglutide to once weekly tirzepatide.
    Urva S; Levine JA; Schneck K; Tang CC
    Curr Med Res Opin; 2024 Apr; 40(4):567-574. PubMed ID: 38407177
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Real-World Glycemic Control from GLP-1RA Therapy with and Without Concurrent Insulin in Patients with Type 2 Diabetes.
    Singhal M; Unni S; Schauerhamer M; Nguyen H; Hurd J; McAdam-Marx C
    J Manag Care Spec Pharm; 2017 Mar; 23(3):267-275. PubMed ID: 28230449
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Real-world evidence of the effectiveness on glycaemic control of early simultaneous versus later sequential initiation of basal insulin and glucagon-like peptide-1 receptor agonists.
    Rosenstock J; Ampudia-Blasco FJ; Lubwama R; Peng XV; Boss A; Shi L; Fonseca V
    Diabetes Obes Metab; 2020 Dec; 22(12):2295-2304. PubMed ID: 32729183
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preference for Oral and Injectable GLP-1 RA Therapy Profiles in Japanese Patients with Type 2 Diabetes: A Discrete Choice Experiment.
    Igarashi A; Bekker Hansen B; Langer J; Tavella F; Collings H; Davies N; Wyn R
    Adv Ther; 2021 Jan; 38(1):721-738. PubMed ID: 33245530
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adherence, persistence, glycaemic control and costs among patients with type 2 diabetes initiating dulaglutide compared with liraglutide or exenatide once weekly at 12-month follow-up in a real-world setting in the United States.
    Mody R; Huang Q; Yu M; Zhao R; Patel H; Grabner M; Landó LF
    Diabetes Obes Metab; 2019 Apr; 21(4):920-929. PubMed ID: 30520248
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Real-world study of flash glucose monitoring among adults with type 2 diabetes within the Swedish National Diabetes Register.
    Eeg-Olofsson K; Svensson AM; Franzén S; Ahmed Ismail H; Törnblom M; Levrat-Guillen F
    Diab Vasc Dis Res; 2023; 20(1):14791641211067418. PubMed ID: 36715353
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Clinical Effectiveness and Safety of Once-Weekly GLP-1 Receptor Agonist Dulaglutide as Add-On to Metformin or Metformin Plus Insulin Secretagogues in Obesity and Type 2 Diabetes.
    Mirabelli M; Chiefari E; Tocci V; Caroleo P; Giuliano S; Greco E; Luque RM; Puccio L; Foti DP; Aversa A; Brunetti A
    J Clin Med; 2021 Mar; 10(5):. PubMed ID: 33801192
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Important Decrease in Hospitalizations for Acute Diabetes Events Following FreeStyle Libre System Initiation in People with Type 2 Diabetes on Basal Insulin Therapy in France.
    Guerci B; Roussel R; Levrat-Guillen F; Detournay B; Vicaut E; De Pouvourville G; Emery C; Riveline JP
    Diabetes Technol Ther; 2023 Jan; 25(1):20-30. PubMed ID: 36094418
    [No Abstract]   [Full Text] [Related]  

  • 36. Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.
    Lin J; Lingohr-Smith M; Fan T
    Clinicoecon Outcomes Res; 2017; 9():19-29. PubMed ID: 28053550
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Switching to iGlarLixi versus continuation of a daily or weekly glucagon-like peptide-1 receptor agonist (GLP-1 RA) in insufficiently controlled type 2 diabetes: A LixiLan-G trial subgroup analysis by HbA1c and GLP-1 RA use at screening.
    Rosenstock J; Blonde L; Aroda VR; Frias J; Souhami E; Ji C; Niemoeller E; Del Prato S
    Diabetes Obes Metab; 2021 Jun; 23(6):1331-1341. PubMed ID: 33565209
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment Patterns and Persistence With GLP-1 RA Treatments Among Patients With Type 2 Diabetes in France: A Retrospective Cohort Analysis.
    Zimner Rapuch S; Divino V; Norrbacka K; Boye K; Lebrec J; Rosilio M; DeKoven M; Guerci B
    Diabetes Ther; 2021 May; 12(5):1553-1567. PubMed ID: 33864629
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Insulin-glucagon-like peptide-1 receptor agonist relay and glucagon-like peptide-1 receptor agonist first regimens in individuals with type 2 diabetes: A randomized, open-label trial study.
    Takeshita Y; Kita Y; Tanaka T; Goto H; Nakano Y; Teramura C; Enyama Y; Takamura T;
    J Diabetes Investig; 2022 Jun; 13(6):965-974. PubMed ID: 35034428
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.